摘要
目的探讨二甲双胍辅助化疗治疗对卵巢癌患者术后外周血D-二聚体、溶血磷脂酸(LPA)和白细胞介素-6 (IL-6)水平的影响。方法选取2017年1月至2018年6月间昆明医科大学附属肿瘤医院收治的100例卵巢癌术后患者,按照不同治疗方法分为顺铂组和联合组,每组50例。顺铂组患者采用顺铂联合紫杉醇(TC方案)化疗治疗,联合组患者采用二甲双胍辅助化疗方案治疗,比较两组患者的临床疗效和外周血D-二聚体、LPA及IL-6水平。结果顺铂组患者治疗有效率和控制率分别为28. 0%和68. 0%,联合组患者分别为46. 0%和80. 0%,联合组均高于顺铂组患者,差异均有统计学意义(均P <0. 05)。治疗后,联合组患者外周血D-二聚体、LPA和IL-6水平均优于顺铂组,差异均有统计学意义(均P <0. 05)。结论二甲双胍辅助顺铂对卵巢癌患者术后的预后作用积极,可提高临床疗效,改善外周血D-二聚体、LPA和IL-6水平,值得临床推行。
Objective To analyze the effects of adjuvant metformin chemotherapy on the levels of D-dimer,lysophosphatidic acid( LPA) and interleukin-6( IL-6) in peripheral blood in patients with ovarian cancer after operation. Methods A total of 100 patients with ovarian cancer treated at Cancer Hospital Affiliated to Kunming Medical University from January 2017 to June 2018 were selected and divided into cisplatin group and combination group according to different treatment methods with 50 patients in each group.Cisplatin group was treated with cisplatin plus paclitaxel( TC regimen),and the combination group was treated with metformin adjuvant to chemotherapy regimen. The clinical efficacy,and the levels of D-dimer,LPA and IL-6 in peripheral blood was compared between the two groups. Results The efficacy rate and control rate was 28. 0% and 68. 0% respectively for the cisplatin group and 46. 0% and 80. 0% respectively for the combination group with the combination group higher than the cisplatin group( all P < 0. 05). After treatment,the levels of D-dimer,LPA and IL-6 in peripheral blood were better in the combination group than in the cisplatin group( all P < 0. 05). Conclusion Adjuvant metformin chemotherapy has a positive effect on the prognosis in patients with ovarian cancer after operation. It can improve the clinical efficacy and the levels of D-dimer,LPA and IL-6 in peripheral blood,and it is worthy of clinical application
作者
刘坤
付凤莲
杨勇
杨梅
陈云兰
鲁凤丽
LIU Kun;FU Feng-lian;YANG Yong;YANG Mei;CHEN Yun-lan;LU Feng-li(Department of Cadre Ward ,Cancer Hospital Affiliated to Kunming Medical University,Kunming 650118,China;Department of Urology,Cancer Hospital Affiliated to Kunming Medical University,Kunming 650118,China)
出处
《中国肿瘤临床与康复》
2019年第1期70-72,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
云南省卫计委资助项目(2014NS026)